Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADOPT: ADT + MDRT in Oligo-recurrent Prostate Cancer
NCT04302454Phase 3Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2020
- Primary completion
- Oct 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of leuprolide in prostate cancer (PCa) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Metastases Progression-Free Survival at 2.5 years. Started Mar 2020; status: active, not recruiting.
02
Drugs
leuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04302454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04302454.